泰合生技药品股份有限公司

  • 商品介绍
  • 规格参数
  •   泰合生技药品股份有限公司(股票代号:6467)成立于2010年,为一从事药物传输系统(Drug Delivery System, DDS)的特色研发药厂,公司以透上皮传输技术(Transepithelial Delivery System, TDS)为主要技术,专攻中枢神经系统及癌症安宁照顾二大领域的新剂型市场。产品以贴片(Patch)及口溶膜(ODF)为主。DDS是以现有药品的原料药为基础,藉由改变传输途径,以提供更安全、舒适的方式将药物传送至体内,亦可大幅提高病人服从医嘱性。由于每年皆有超过数十亿美元的畅销药品面临专利到期,透过改变剂型可以延长药品的专利及知识产权,尤其是目前的贴片/口溶膜产品数量少、市场竞争不多,且此类药品开发的成功率远大于新成分新药,开发时间也小于新成分新药。泰合致力新药开发的同时,也利用自有技术平台来开发保健、保养品,发展非药品事业。

    TAHO Pharmaceuticals Ltd. (TAHO) is a specialty pharmaceutical company focused on the development of pharmaceutical products based on its drug delivery technology platforms to relieve the debilitating side effects of cancer treatment and treat central nervous system (CNS) conditions. TAHO utilizes its proprietary drug delivery technologies to create products that improve the quality of life for patients by improving the health of people safely, scientifically, innovatively and efficiently throughout the world.Also TAHO utilizes its proprietary Transepithelial Delivery System (TDS) technology to create skincare and healthcare products to develop non-pharmaceutical business.